Introduction {#sec1-1}
============

Dyslipidemia is a major risk factor for the development of cardiovascular disease, and the proper treatment and prevention of dyslipidemia can reduce the cardiovascular morbidity and mortality ([@ref1]). Angiotensin-converting enzyme inhibitors (ACEIs) have been shown to reduce the incidence of major adverse cardiac events (MACEs) and death following myocardial infarction through the enhancement of the endothelial function, cardiovascular remodeling, and the inhibition of the progression of atherosclerosis ([@ref2],[@ref3]). Angiotensin II type I (AT1) receptor blockers (ARBs) are an alternative to ACEIs for patients intolerant to ACEIs ([@ref4]-[@ref7]). Although previous studies, such as the Heart Outcomes Prevention Evaluation Study (HOPE) ([@ref8]), EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) ([@ref9]), and Valsartan in Acute Myocardial Infarction Trial (VALIANT) ([@ref10]) trials, showed the beneficial roles of ACEIs or ARBs in improving cardiovascular outcomes, these comparative studies were not focused on dyslipidemia. Furthermore, Borghi et al. ([@ref11]) and other investigators ([@ref12]-[@ref14]) suggested that the overexpressed AT1 receptor, as well as an increased affinity of such receptors for circulating and locally released angiotensin II, is present in patients with hypercholesterolemia. Therefore, ACEIs and ARBs inhibit the production of angiotensin II or it's binding to the AT1 receptor in these patients.

The Survival of Myocardial Infarction Long-Term Evaluation trial ([@ref15]) and its post-hoc analysis ([@ref16]) have suggested that the early treatment with zofenopril was more effective in reducing the morbidity and mortality in patients with acute myocardial infarction (AMI) and hypercholesterolemia compared to patients in the placebo and the normocholesterolemic groups. Another study reported that candesartan was better than felodipine with regard to its capacity to improve hypercholesterolemia-associated endothelial dysfunction ([@ref17]). Currently, there are limited comparative data concerning the long-term major clinical outcomes following ACEIs and ARBs therapy in AMI patients with dyslipidemia. Hence, we investigated 2-year major clinical outcomes of the ACEIs and ARBs therapy in patients with AMI with dyslipidemia after a successful stent implantation.

Methods {#sec1-2}
=======

Study population {#sec2-1}
----------------

The present nonrandomized, multicenter, observational, and retrospective cohort study is based on data from the Korea AMI Registry (KAMIR). The characteristics and detailed information of this registry have already been published ([@ref18]). A total of 5185 patients with AMI in the KAMIR from November 2005 to June 2015 were evaluated. Patients were excluded from the study based on the following criteria: ([@ref1]) incomplete laboratory results (n=1321, 25.5%); ([@ref2]) loss to follow-up or those who did not participate (n=113, 2.2%); ([@ref3]) ACEIs or ARBs had not been prescribed (n=732, 14.1%); and ([@ref4]) concomitant use of ACEIs and ARBs (n=26, 0.5%). Finally, a total of 3015 AMI patients who underwent a successful stent implantation and were prescribed ACEIs (n=2175, 72.1%) or ARBs (n=840, 27.9%) were enrolled ([Fig. 1](#F1){ref-type="fig"}). The selection of treatment strategies, i.e., either ACEIs or ARBs, after a percutaneous coronary intervention (PCI) was based on the physician's preferences. All data were collected at each participating center using a web-based case report form. This study protocol was approved by the Institutional Review Board of each participating center. In addition, this study was conducted in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Informed consent was obtained from all patients prior to their enrollment. We tracked the enrolled patients via face-to-face interviews, phone calls, and chart reviews ([@ref19]).

![Flow chart AMI - acute myocardial infarction, KAMIR - Korea Acute Myocardial Infarction Registry, ACEIs - angiotensin converting enzyme inhibitors, ARBs - angiotensin II type I receptor blockers](AJC-23-86-g001){#F1}

PCI procedure and medical treatment {#sec2-2}
-----------------------------------

The diagnostic coronary angiography and PCI were performed through the femoral and the radial artery approach using the standard technique ([@ref20]). Before CAG, the loading of dual antiplatelet therapy (DAPT) was as follows: 200 to 300 mg of aspirin and 300 to 600 mg of clopidogrel; and 180 mg ticagrelor or 60 mg prasugrel could also be used as alternatives to clopidogrel. The total duration of DAPT recommended for patients who underwent PCI was \>12 months ([@ref21]).

Study definitions and clinical outcomes {#sec2-3}
---------------------------------------

The presence of dyslipidemia was defined as the positive history of having dyslipidemia regardless of the presence or absence of receiving lipid-lowering agents or receiving lipid-lowering agents regardless of the presence or absence of having history of dyslipidemia. Although some patients did not have a previous history of dyslipidemia or were not administered with lipid-lowering agents, their laboratory results were compatible with the diagnostic criteria of dyslipidemia, they were considered as patients with dyslipidemia in this study ([@ref22]). Because the definition of dyslipidemia varies according to different guidelines and races, we defined dyslipidemia according to the Asian guideline ([@ref23]), i.e., the patients with 12-hour fasting serum low-density lipoprotein (LDL) cholesterol concentrations of at least 140 mg/dL, high-density lipoprotein (HDL) cholesterol concentrations \<40 mg/dL, and triglyceride (TG) concentrations ≥150 mg/dL. We defined STEMI and NSTEMI according to the current guidelines ([@ref5]-[@ref7]). MACEs were the major clinical endpoint of this study; they were defined as all-cause death, recurrent myocardial infarction (Re-MI), and any coronary repeat revascularization during the 2-year follow-up period. All-cause death was classified as cardiac (CD) or non-CD. Any repeat-revascularization-comprised TLR, TVR, and non-TVR. Previously ([@ref22]), we have published the definitions of Re-MI, TLR, TVR, and non-TVR.

Statistical analysis {#sec2-4}
--------------------

For continuous variables, in this study, the normality test was performed using the Kolmogorov--Smirnov normality test. According to the normality results, the independent samples t-test or Mann--Whitney U test were applied to examine the difference of continuous variables means or medians of the two groups, and the data were expressed as the mean±standard deviations. For categorical variables, the differences between the two groups were analyzed using the chi-squared test or, if not applicable, Fisher's exact test, and the data were expressed as counts and percentages. Various clinical outcomes were estimated using the Kaplan--Meier method, and differences between the two groups were compared using the log-rank test. We included only meaningful confounding covariates (p\<0.001, or those having predictive values) during the multiple Cox proportional hazard regression analysis, as shown in [Table 1](#T1){ref-type="table"}. For all analyzes, two-sided p-values \<0.05 were considered statistically significant. All statistical analyzes were performed using the SPSS software, version 20 (IBM; Armonk, NY, USA).

###### 

Clinical outcomes at 2-year

  Outcomes                 Cumulative Events at 2-year (%)   Unadjusted   *P*-value   [\*](#t1f1){ref-type="table-fn"}Adjusted   *P*-value                          
  ------------------------ --------------------------------- ------------ ----------- ------------------------------------------ ----------- ---------------------- -------
  MACEs                    150 (7.1)                         79 (10.2)    0.010       1.424 (1.085--1.871)                       0.011       1.305 (0.911--1.869)   0.146
   All-cause death         39 (1.8)                          30 (3.7)     0.003       2.044 (1.269--3.290)                       0.003       2.277 (1.154--4.495)   0.018
    Cardiac death          34 (1.6)                          24 (3.0)     0.017       1.870 (1.109--3.154)                       0.019       2.019 (0.979--4.163)   0.057
   Re-MI                   32 (1.5)                          19 (2.6)     0.101       1.600 (0.907--2.824)                       0.105       1.203 (0.539--2.685)   0.652
   Any revascularization   88 (4.3)                          39 (5.2)     0.309       1.216 (0.834--1.772)                       0.310       1.159 (0.720--1.866)   0.543
    TLR                    23 (1.1)                          16 (2.1)     0.045       1.900 (1.004--3.596)                       0.049       2.058 (0.881--4.809)   0.096
    TVR                    47 (2.3)                          28 (3.8)     0.036       1.640 (1.027--2.618)                       0.038       1.551 (0.854--2.816)   0.149
    Non-TVR                42 (2.0)                          12 (1.6)     0.448       0.780 (0.411--1.482)                       0.449       0.733 (0.326--1.651)   0.454

Adjusted by age, gender, LVEF, BMI, STEMI, NSTEMI, hypertension, diabetes, previous MI, previous PCI, previous CVA, peak CK-MB, peak troponin-I, serum level of NT-ProBNP, creatinine, total cholesterol, LDL cholesterol, discharge medications (aspirin, clopidogrel, ticagrelor, prasugrel, cilostazole, BB, CCB), infarct-related artery (IRA), treated vessel (LCx), ACC/AHA lesion type B2 and C, types of stent (BMS, SES, PES, BES), and stent diameter.

CI - confidence interval; MACE - major adverse cardiac events; Re-MI - re-myocardial infarction; TLR - target lesion revascularization; TVR - target vessel revascularization;

LVEF - left ventricular ejection fraction; BMI - body mass index; STEMI - ST-segment elevation myocardial infarction; NSTEMI - non-ST-segment elevation myocardial infarction;

PCI - percutaneous coronary intervention; CVA - cerebrovascular accident; CK-MB - creatine kinase myocardial band; NT-ProBNP - N-terminal pro-brain natriuretic peptide;

LDL - low-density lipoprotein; BBs - beta-blockers; CCBs - calcium-channel blockers; LAD - left anterior descending coronary artery; LCx - left circumflex coronary artery; ACC/AHA - American College of Cardiology/American Heart Association; BMS - bare-metal stent; SES - sirolimus-eluting stent; PES - paclitaxel-eluting stent; BES - biolimus-eluting stent

Results {#sec1-3}
=======

Baseline characteristics {#sec2-5}
------------------------

The baseline, laboratory, angiographic, and procedural characteristics of this study population are summarized in [Table 2](#T2){ref-type="table"}. This study population comprised patients who had a relatively well preserved left ventricular ejection fraction (LVEF; mean, 53.3%±10.9%). The mean age of the patients in the ARBs group was higher than that of those in the ACEIs group (62.6±11.7 years vs. 59.9±11.9 years, p\<0.001). The numbers of male patients, STEMI cases, and NSTEMI cases; the peak levels of creatine kinase myocardial band (CK-MB) and troponin-I; the total cholesterol and LDL-cholesterol levels; the prescription rates of clopidogrel, cilostazol, beta-blockers (BBs), and calcium-channel blockers (CCBs); and the number of cases with American College of Cardiology/American Heart Association (ACC/AHA) type C lesions were higher in case of the ACEIs group than in case of the ARBs group. In contrast, the ARBs group showed higher mean values of body mass index; a greater number of cases with hypertension, diabetes mellitus (DM), and previous history of heart disease (MI, PCI, and cerebrovascular accidents); higher levels of blood N-terminal pro-brain natriuretic peptide and serum creatinine; higher prescription rates of ticagrelor and prasugrel; higher incidence of the left anterior descending coronary artery being as the infarct-related artery (IRA) and the left circumflex coronary artery being the treated vessel; and a greater number of cases with the ACC/AHA type B2 lesions than in the ACEIs group. Even though newly developed antiplatelet agents (ticagrelor, prasugrel) were more frequently prescribed among patients in the ARBs group, the total number of patients in who these agents were prescribed was small. The first-generation DESs (sirolimus-eluting stent and paclitaxel-eluting stent) were more frequently deployed among patients from the ACEIs group, and the biolimus-eluting stent was more frequently deployed among patients from the ARBs group. The incidence of the deployment of the zotarolimus-eluting stent and everolimus-eluting stent among the patients from the two groups was similar. Even though the length of the deployed stents and the number of deployed stents were similar between the two groups, the diameter of the deployed stent was larger in case of patients from the ACEIs group than in cases of those from the ARBs group. In addition, the numbers of cases showing cardiogenic shock, and cardiopulmonary resuscitation (CPR) on admission, and the incidence of the use of intravascular ultrasound (IVUS), optical coherence tomography (OCT), and fractional flow reserve (FFR) among the patients from the two groups were similar.

###### 

Baseline clinical, laboratory, and procedural characteristics

  Variables                                   ACEIs (n=2175)   ARBs (n=840)    *P*-value
  ------------------------------------------- ---------------- --------------- -----------
  Age (years)                                 59.9±11.9        62.6±11.7       \<0.001
  Gender (men)                                1641 (75.4)      599 (71.3)      0.020
  LVEF (%)                                    53.0±10.8        54.1±10.8       0.010
  Body mass index (kg/m^2^)                   24.8±3.1         25.1±3.3        0.021
  Systolic blood pressure (mm Hg)             134.0±27.0       133.2±28.3      0.483
  Diastolic blood pressure (mm Hg)            81.0±16.2        80.0±16.7       0.180
  Cardiogenic shock, n (%)                    73 (3.4)         33 (3.9)        0.444
  CPR on admission, n (%)                     50 (2.3)         21 (2.5)        0.744
  STEMI, n (%)                                1199 (55.1)      384 (45.7)      \<0.001
   Primary PCI, n (%)                         1121 (93.5)      354 (92.2)      0.377
   CABG, n (%)                                3/1199 (0.3)     2/384 (0.5)     0.600
  NSTEMI, n (%)                               976 (44.9)       456 (54.3)      \<0.001
   PCI within 24 hours                        758 (77.7)       357 (78.3)      0.791
   CABG, n (%)                                2/976 (0.2)      3/456 (0.7)     0.335
  Hypertension, n (%)                         1237 (56.9)      603 (71.8)      \<0.001
  Diabetes mellitus, n (%)                    685 (31.5)       340 (40.5)      \<0.001
  Previous myocardial infarction, n (%)       118 (5.4)        88 (10.5)       \<0.001
  Previous PCI, n (%)                         194 (8.9)        148 (17.6)      \<0.001
  Previous CABG, n (%)                        15 (0.7)         7 (0.8)         0.678
  Previous CVA, n (%)                         131 (6.0)        91 (10.8)       \<0.001
  Previous heart failure, n (%)               35 (1.6)         19 (2.3)        0.226
  Peak CK-MB (mg/dL)                          119.0±170.0      103.5±173.2     0.027
  Peak troponin-I (ng/mL)                     46.9±139.7       34.9±51.4       0.002
  NT-ProBNP (pg/mL)                           1280.4±3715.1    2235.5±5687.6   0.001
  hs-CRP (mg/dL)                              10.7±68.0        14.5±70.8       0.237
  Serum creatinine (mg/L)                     1.03±0.81        1.26±1.53       \<0.001
  Blood glucose (mg/dL)                       165.5±71.9       169.9±81.0      0.176
  Total cholesterol (mg/dL)                   192.3±50.1       178.9±50.2      \<0.001
  Triglyceride (mg/L)                         156.8±117.4      150.8±116.9     0.222
  HDL cholesterol (mg/L)                      43.6±13.8        42.5±15.7       0.098
  LDL cholesterol (mg/L)                      121.5±41.7       111.0±42.7      \<0.001
  Discharge medications                                                        
   Aspirin, n (%)                             2165 (99.5)      832 (99.0)      0.115
   Clopidogrel, n (%)                         2016 (92.7)      718 (85.5)      \<0.001
   Ticagrelor, n (%)                          79 (3.6)         78 (9.3)        \<0.001
   Prasugrel, n (%)                           61 (2.8)         36 (4.3)        0.039
   Cilostazole, n (%)                         545 (25.1)       174 (20.7)      0.012
   Beta-blocker, n (%)                        1939 (89.1)      713 (84.9)      0.001
   Calcium channel blockers, n (%)            147 (6.8)        112 (13.3)      \<0.001
   Lipid lowering agents                      1943 (89.3)      742 (88.3)      0.430
  Angiographic & procedural characteristics                                    
  Infarct-related artery                                                       
   Left main, n (%)                           26 (1.2)         22 (2.6)        0.005
   Left anterior descending, n (%)            1001 (46.0)      382 (45.5)      0.787
   Left circumflex, n (%)                     398 (18.3)       156 (18.6)      0.862
   Right coronary artery, n (%)               750 (34.5)       280 (33.3)      0.551
  Treated vessel                                                               
   Left main, n (%)                           48 (2.2)         29 (3.5)        0.052
   Left anterior descending, n (%)            1196 (55.0)      466 (55.5)      0.809
   Left circumflex, n (%)                     578 (26.6)       262 (31.2)      0.011
   Right coronary artery, n (%)               901 (41.4)       341 (40.6)      0.678
  ACC/AHA lesion type                                                          
   Type B1, n (%)                             288 (13.2)       131 (15.6)      0.094
   Type B2, n (%)                             587 (27.0)       285 (33.9)      \<0.001
   Type C, n (%)                              1086 (49.9)      333 (39.6)      \<0.001
  Extent of coronary artery disease                                            
   1-vessel, n (%)                            1037 (47.7)      393 (46.8)      0.660
   2-vessel, n (%)                            665 (30.6)       273 (32.5)      0.306
   ≥ 3-vessel, n (%)                          473 (21.7)       174 (20.7)      0.536
   Multivessel disease, n (%)                 1138 (52.3)      447 (53.2)      0.660
  IVUS, n (%)                                 360 (21.9)       170 (24.0)      0.247
  OCT, n (%)                                  7 (1.3)          7 (2.0)         0.438
  FFR, n (%)                                  11 (2.1)         2 (0.6)         0.069
  Stents                                                                       
   BMS, n (%)                                 185 (8.5)        37 (4.4)        \<0.001
   SES, n (%)                                 323 (14.8)       84 (10.0)       \<0.001
   PES, n (%)                                 311 (14.3)       89 (10.6)       0.007
   ZES, n (%)                                 501 (23.0)       205 (24.4)      0.426
   EES, n (%)                                 643 (29.6)       272 (32.4)      0.131
   BES, n (%)                                 117 (5.4)        105 (12.5)      \<0.001
   Others, n (%)                              280 (12.9)       85 (10.1)       0.021
  Stent diameter (mm)                         3.15±0.43        3.11±0.43       0.027
  Stent length (mm)                           26.0±9.3         26.5±10.5       0.248
  Number of stent                             1.49±0.81        1.53±0.84       0.278

Values are presented as the mean±SD or numbers and percentages. The *P*-values for continuous data were obtained from the analysis of the unpaired t-test. The *P*-values for categorical data were obtained from the chi-squared test.

LVEF - left ventricular ejection fraction; STEMI - ST-segment elevation myocardial infarction; NSTEMI - non-STEMI; PCI - percutaneous coronary intervention; CABG - coronary artery bypass graft; CVA - cerebrovascular accidents; CK-MB - creatine kinase myocardial band; NT-ProBNP - N-terminal pro-brain natriuretic peptide; hs-CRP -high-sensitivity C-reactive protein; HDL - high-density lipoprotein; LDL - low-density lipoprotein; ACC/AHA - American College of Cardiology/American Heart Association; IVUS - intravascular ultrasound;

OCT - optical coherence tomography; FFR - fractional flow reserve, BMS - bare-metal stent; SES - sirolimus-eluting stents; PES - paclitaxel-eluting stents; ZES - zotarolimus-eluting stents; EES - everolimus-eluting stents; BES - biolimus-eluting stents

Clinical outcomes {#sec2-6}
-----------------

[Table 1](#T1){ref-type="table"} and [Figure 2](#F2){ref-type="fig"} show the cumulative incidences of the major clinical outcomes during the 2-year follow-up period. Before the adjustment, the cumulative incidences of MACEs \[hazard ratio (HR), 1.424; 95% confidence interval (CI), 1.085--1.871; p=0.011\], all-cause death (HR, 2.044; 95% CI, 1.269--3.290; p=0.003), CD (HR, 1.870; 95% CI, 1.109--3.154; p=0.019), TLR (HR, 1.900; 95% CI, 1.004--3.596; p=0.049) and TVR (HR, 1.640; 95% CI, 1.027--2.618; p=0.038) were significantly higher in the ARBs group than in the ACEIs group. However after the adjustment, the cumulative incidences of MACEs \[adjusted HR (aHR), 1.305; 95% CI, 0.911--1.869; p=0.146\], cardiac death (aHR, 2.019; 95% CI, 0.979--4.163; p=0.057), Re-MI (aHR, 1.203; 95% CI, 0.539--2.685; p=0.652), any repeat revascularization (aHR, 1.159; 95% CI, 0.720--1.866; p=0.543), TLR (aHR, 2.058; 95% CI, 0.881--4.809; p=0.096), TVR (aHR, 1.551; 95% CI, 0.854--2.816; p=0.149), and non-TVR (aHR, 0.733; 95% CI, 0.326--1.651; p=0.454) among the two groups were similar. However, the cumulative incidence of all-cause death in the ARB group was significantly higher than that in the ACEI group (aHR, 2.277; 95% CI, 1.154--4.495; p=0.018). [Table 3](#T3){ref-type="table"} shows the independent predictors for MACEs and all-cause death at the 2-year time point. An advanced age (≥65 years, aHR, 1.431; 95% CI, 1.071--1.911; p=0.015) CPR on admission (aHR, 1.951; 95% CI, 1.009--3.776; p=0.047), and multivessel disease (aHR, 1.698; 95% CI, 1.275--2.262; p\<0.001) were significant independent predictors for MACEs. An advanced age (≥65 years, aHR, 2.765; 95% CI, 1.584--4.826; p\<0.001), decreased LVEF (\<50%, aHR, 1.859; 95% CI, 1.144--3.022; p=0.012), and CPR on admission (aHR, 2.916; 95% CI, 1.114--7.630; p=0.029) were meaningful independent predictors for all-cause death. In female patients, and patients with decreased LVEF and non-cardiogenic shock, ACEIs may be preferred instead of ARBs to reduce the incidence of MACEs after stent implantation ([Fig. 3a](#F3){ref-type="fig"}). In addition, ACEIs are preferred to ARBs in male patients and patients with decreased LVEF and non-cardiogenic shock to reduce the incidence of all-cause death ([Fig. 3b](#F3){ref-type="fig"}).

###### 

Independent predictors for MACEs and all-cause death at 2 years in total study population

  Variables                  MACEs Univariate HR (95% CI)   *P*-value   Multiple HR (95% CI)   *P*-value   All-Cause Death Univariate HR (95% CI)   *P*-value   Multiple HR (95% CI)   *P*-value
  -------------------------- ------------------------------ ----------- ---------------------- ----------- ---------------------------------------- ----------- ---------------------- -----------
  ACEIs vs. ARBs             1.424 (1.085--1.871)           0.011       1.371 (1.035--1.817)   0.028       2.044 (1.269--3.290)                     0.003       1.840 (1.127--3.003)   0.015
  Age (≥65 years)            1.676 (1.293--2.171)           \<0.001     1.431 (1.071--1.911)   0.015       3.875 (2.320--6.471)                     \<0.001     2.765 (1.584--4.826)   \<0.001
  Gender (men)               1.290 (0.974--1.708)           0.076       1.056 (0.776--1.437)   0.728       2.115 (1.311--3.411)                     0.002       1.307 (0.779--2.193)   0.310
  LVEF (\<50%)               1.324 (1.016--1.726)           0.037       1.160 (0.881--1.527)   0.289       2.315 (1.442--3.751)                     0.001       1.859 (1.144--3.022)   0.012
  Hypertension               1.330 (1.009--1.753)           0.043       1.132 (0.846--1.514)   0.405       1.819 (1.063--3.113)                     0.029       1.304 (0.748--3.273)   0.350
  Diabetes mellitus          1.512 (1.164--1.964)           0.002       1.286 (0.965--1.665)   0.088       1.792 (1.117--2.874)                     0.015       1.339 (0.823--2.177)   0.239
  Cardiogenic shock          1.590 (0.889--2.842)           0.118       1.378 (0.758--2.503)   0.293       1.714 (0.624--4.705)                     0.296       1.197 (0.420--3.408)   0.736
  CPR on admission           2.018 (1.070--3.803)           0.030       1.951 (1.009--3.776)   0.047       3.377 (1.359--8.390)                     0.009       2.916 (1.114--7.630)   0.029
  Beta-blocker               0.875 (0.599--1.278)           0.490       1.102 (0.750--1.618)   0.621       0.812 (0.415--1.587)                     0.542       0.963 (0.486--1.911)   0.915
  Prasugrel                  1.376 (0.567--3.337)           0.481       1.217 (0.495--2.993)   0.669       2.144 (0.289--15.45)                     0.449       1.777 (0.239--13.20)   0.574
  Ticagrelor                 1.576 (0.700--3.550)           0.272       2.029 (0.824--4.998)   0.124       \-                                       \-          \-                     \-
  Lipid-lowering agent       1.283 (0.883--1.864)           0.191       1.170 (0.798--1.716)   0.422       1.860 (1.017--3.400)                     0.044       1.637 (0.888--3.017)   0.114
  ACC/AHA type B2/C lesion   1.240 (0.902--1.704)           0.186       1.290 (0.925--1.798)   0.133       1.068 (0.610--1.867)                     0.819       1.246 (0.691--2.248)   0.465
  MVD                        1.887 (1.430--2.489)           \<0.001     1.698 (1.275--2.262)   \<0.001     1.476 (0.907--2.402)                     0.117       1.134 (0.688--1.868)   0.956
  Stent diameter             0.799 (0.584--1.093)           0.161       0.931 (0.673--1.289)   0.667       0.682 (0.381--1.222)                     0.199       0.955 (0.522--1.750)   0.883
  Stent length               1.006 (0.993--1.020)           0.343       1.002 (0.987--1.016)   0.832       1.006 (0.983--1.031)                     0.600       1.001 (0.974--1.029)   0.945

ACEIs - angiotensin-converting-enzyme inhibitors; ARBs - angiotensin II type 1 receptor blockers; HR - hazard ratio; LVEF - left ventricular ejection fraction; CPR - cardiopulmonary resuscitation; ACC/AHA - American College of Cardiology/American Heart Association; MVD - multivessel disease

![Kaplan--Meier curved analysis for MACEs (a), all-cause death (b), cardiac death (c), Re-MI (d), any repeat revascularization (e), TLR (f), TVR (g), and non-TVR (h) MACEs - major adverse cardiac event, ACEIs - angiotensin converting enzyme inhibitors, ARBs - angiotensin II type I receptor blockers, re-MI - recurrent myocardial infarction, TLR - target lesion revascularization, TVR - target vessel revascularization](AJC-23-86-g002){#F2}

![Subgroup analysis for MACEs (a) and all-cause death (b) MACEs - major adverse cardiac events, LVEF - left ventricular ejection fraction, STEMI - ST-segment elevation myocardial infarction, ACC/AHA - American College of Cardiology/American Heart Association, ACEIs - angiotensin converting enzyme inhibitors, ARBs - angiotensin II type I receptor blockers, CI - confidence interval](AJC-23-86-g003){#F3}

Discussion {#sec1-4}
==========

The main findings of this study are the following: ([@ref1]) the cumulative incidence all-cause death in the ARBs group was significantly higher than that in the ACEIs group, ([@ref2]) the cumulative incidences of MACE, CD, Re-MI, and any repeat revascularization including TLR, TVR, and non-TVR were similar between the two groups, and ([@ref3]) an advanced age (≥65 years), decreased LVEF(\<50%), and CPR on admission were statistically significant independent predictors for all-cause death.

ACEIs are recommended with Class I, starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes, or anterior infarct. Also, ACEIs should be considered in all patients in the absence of contraindications as Class IIa according to the ESC STEMI guidelines 2017 ([@ref4]).

Dyslipidemia is a major predictor for cardiovascular clinical outcomes after AMI ([@ref22]). Recently, many studies have focused on a high-dose statin therapy to reduce the risk of cardiovascular death, Re-MI, and coronary revascularization in AMI patients ([@ref24]-[@ref26]), but not on the important roles of ACEIs or ARBs ([@ref4]-[@ref7]). It has been reported that circulating LDL-cholesterol/apolipoprotein B particles may be involved in promoting the upregulation of AT1 receptor genes and this leads to the structural overexpression of vascular AT1 receptors for angiotensin II in cultured vascular smooth muscle cells, as well as in hypercholesterolemic rabbits ([@ref13],[@ref27]). The relationship between the renin-angiotensin system (RAS) and lipid disorders has been investigated in humans ([@ref28]). The increased availability of angiotensin II triggers the atherosclerotic process and promotes the further activation of the RAS ([@ref29]). Hence, these previous reports support the rationale for the use of RAS inhibitors in patients with lipid disorders. A Japanese study ([@ref30]) has shown that compared to amlodipine, telmisartan could treat both the hemodynamic and metabolic aberrations seen in patients with metabolic syndrome. Considering previous reports ([@ref15]-[@ref17], [@ref30]) the possibility of a favorable interaction between RAS inhibitors and the prevention of cardiovascular disease in patients with hypercholesterolemia has been suggested.

Even though the beneficial effects of ACEIs and ARBs on reducing the incidence of MACEs in patients with AMI have been well established ([@ref3], [@ref31], [@ref32]), the relative superiority of ACEIs and ARBs with regard to long-term clinical outcomes is still debatable ([@ref32],[@ref33]). ACEIs play important roles in the conversion of angiotensin I to angiotensin II and catalyze the breakdown of bradykinin to inactive peptides, and the process leads to the accumulation of bradykinin. Bradykinin exerts numerous beneficial effects on cardiovascular protection, including vasodilation, stimulation of nitric oxide (NO), and production of prostacyclin, endothelium-derived hyperpolarizing factor, and tissue plasminogen activator ([@ref34]). ARBs selectively block the AT1 receptor. Unfortunately, this blockage induces the unwanted elevation of the circulating angiotensin II level through the stimulation of angiotensin II type 2 (AT2) receptors; this increase in the AT2 receptor levels is the main cause of cardiac myocyte hypertrophy and apoptosis, inflammation, plaque instability, and thrombus formation ([@ref35]). In one study, ACEIs were reported to be associated with better survival than ARBs in AMI patients 2--5 years after survival discharge (aHR, 0.53; 95% CI, 0.38--0.74; p\<0.001) ([@ref36]). In terms of reducing the incidence of death, MI, angina, revascularization, or stroke, ARBs and ACEIs have similar capacities (HR, 0.97; 95% CI, 0.91--1.03; p=0.286), as per the VALIANT study ([@ref32]).

We assume that the main causative factor of these results is related with the fact that ACEIs can reduce the level of serum angiotensin II and activate the bradykinin system. In contrast, ARBs may cause the prolonged elevation of the level of angiotensin II level and the upregulation of angiotensin I. It is well known that the elevated serum level of angiotensin II plays an important role in the pathogenesis of coronary artery disease ([@ref37]). Elevated angiotensin II levels may direct an increase in the serum cholesterol levels via the interaction with macrophage AT1 receptors, stimulating 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression and ultimately leading to cholesterol accumulation in the macrophages and foam cell formation ([@ref38]). In this study, despite our attempts to adjust the diverse variables through the multiple Cox proportional hazard analysis, the baseline characteristics ([Table 2](#T2){ref-type="table"}) showed that the proportions of old age (≥65 years, 42.7% vs. 35.4%, p\<0.001), hypertension (71.8% vs. 56.9%, p\<0.001), and DM (40.5% vs. 31.5%, p\<0.001) were significantly higher in the ARBs group than in the ACEIs group. In contrast, the numbers of STEMI cases, the peak levels of CK-MB, and troponin-I, the total cholesterol, and LDL-cholesterol levels, the number of cases with ACC/AHA type C lesions, and the incidence of the use of first-generation DESs were higher in the ACEIs group than in the ARBs group. Hence, we speculate that these differences of baseline characteristics may play important roles in explaining the differences in mortality (e.g., all-cause death, CD) between the two groups. According to the OPTIMAAL study ([@ref33]), the clinical benefits of RAS inhibitors were more profound in the high-risk patients' subgroup, i.e., in patients with anterior MI, decreased LVEF (≤40%), heart failure, prior MI, and tachycardia. Therefore, we thought that these relatively poorer baseline characteristics of the ACEIs group may be related to a more prominent beneficial effect of RAS inhibitors in this group compared with the ARB group.

Lipid-lowering agents, such as statin, may decrease the expression and density of AT1 receptors caused by hypercholesterolemia ([@ref14]) through the improvement of the endothelial responses to angiotensin II stimulation ([@ref39]). In this study, the numbers of patients who were prescribed lipid-lowering agents were similar between the two groups (89.3% vs. 88.3%, p=0.430). Therefore, the influence of statins on the major clinical outcomes may be minimized in this study.

Finally, we think that the results of our study may provide some meaningful information to interventional cardiologists during or after PCI and help them ascertain which treatment strategy, i.e., ACEIs or ARBs treatment, is more appropriate for patients with AMI with dyslipidemia to reduce the incidence of all-cause death.

Study limitations {#sec2-7}
-----------------

This study had several limitations ([@ref21]). First, in this study, some data were under-reported or missing due to limitations of the registry data. Especially, the causes of non-CD are very important to understand the main findings of this study. Unfortunately, we could not provide the detailed causes of non-CD due to the above limitations. Therefore, we think that this is a shortcoming of this study. Second, this study was based on medications administered at discharge, and these registry data did not include the complete information concerning the presence or absence of the changes in the prescription doses of each drug during the follow-up period and long-term drug compliance (especially, crossover between ACEIs and ARBs), and drug-related adverse events; this may act as an important factor causing bias in this study. Third, we defined dyslipidemia according to the Asian guidelines such as the Japan Atherosclerosis Society guidelines; these criteria may differ according to the race and region of the patients. Fourth, the information concerning the criteria for the initiation of ACEIs and ARBs administration and the health situation when the ARBs administration was started were very important determinants for long-term clinical outcomes. However, we could not provide this information due to limitations associated with the registry data; these factors may contribute to bias. Fifth, the achievement of the target blood cholesterol level (i.e., LDL cholesterol) was a very important prognostic parameter after statin therapy during the follow-up period. However, we could not present the follow-up results of these lipid profiles due to limitations of the registry data; this may also represent a bias. Sixth, despite the multiple Cox proportional hazard regression analysis, the results of this study may differ according to the variables not included in this registry or in this analysis.

Conclusion {#sec1-5}
==========

In this study, ACEIs were the preferred treatment modality compared to ARBs for patients with AMI with dyslipidemia, who underwent a successful stent implantation, to reduce the incidence of all-cause death during a 2-year follow-up period. However, additional research is required to determine the clinical implications of these results.

Korea Acute Myocardial infarction Registry (KAMIR) investigators; Myung Ho Jeong, MD, Youngkeun Ahn, MD, Sung Chul Chae, MD, Jong Hyun Kim, MD, Seung-Ho Hur, MD, Young Jo Kim, MD, In Whan Seong, MD, Donghoon Choi, MD, Jei Keon Chae, MD, Taek Jong Hong, MD, Jae Young Rhew, MD, Doo-Il Kim, MD, In-Ho Chae, MD, Junghan Yoon, MD, Bon-Kwon Koo, MD, Byung-Ok Kim, MD, Myoung Yong Lee, MD, Kee-Sik Kim, MD, Jin-Yong Hwang, MD, Myeong Chan Cho, MD, Seok Kyu Oh, MD, Nae-Hee Lee, MD, Kyoung Tae Jeong, MD, Seung-Jea Tahk, MD, Jang-Ho Bae, MD, Seung-Woon Rha, MD, Keum-Soo Park, MD, Chong Jin Kim, MD, Kyoo-Rok Han, MD, Tae Hoon Ahn, MD, Moo-Hyun Kim, MD, Ki Bae Seung, MD, Wook Sung Chung, MD, Ju-Young Yang, MD, Chong Yun Rhim, MD, Hyeon-Cheol Gwon, MD, Seong-Wook Park, MD, Young-Youp Koh, MD, Seung Jae Joo, MD, Soo-Joong Kim, MD, Dong Kyu Jin, MD, Jin Man Cho, MD, Sang-Wook Kim, MD, Jeong Kyung Kim, MD, Tae Ik Kim, MD, Deug Young Nah, MD, Si Hoon Park, MD, Sang Hyun Lee, MD, Seung Uk Lee, MD, Hang-Jae Chung, MD, Jang-Hyun Cho, MD, Seung Won Jin, MD, Myeong-Ki Hong, MD, Yangsoo Jang, MD, Jeong Gwan Cho, MD, Hyo-Soo Kim, MD and Seung Jung Park, MD.

**Funding:** This research was supported by a fund (2016-ER6304-02) by the Research of Korea Centers for Disease Control and Prevention.

**Conflict of interest:** None declared.

**Peer-review:** Externally peer-reviewed.

**Authorship contributions:** Concept -- Y.H.K., A.Y.H., M.K.H.; Design -- Y.H.K., A.Y.H., M.K.H.; Supervision -- Y.H.K., M.H.J., D.C., M.K.H., Y.J.; Funding -- M.H.J.; Materials -- M.H.J., B.K.K., S.J.H., S.K., C.M.A., J.S.K., Y.G.K., D.C., M.K.H., Y.J.; Data collection and/or processing -- Y.H.K., A.Y.H., B.K.K., S.J.H., S.K., C.M.A., J.S.K., Y.G.K.; Analysis and/or interpretation -- Y.H.K., A.Y.H., M.K.H.; Literature search -- Y.H.K., A.Y.H., S.J.H., S.K.; Writing -- Y.H.K., A.Y.H., B.K.K., C.M.A., J.S.K., Y.G.K.; Critical review -- Y.H.K., A.Y.H., M.H.J., D.C., M.K.H., Y.J.

[^1]: Y.H.K. and A.Y.H. are equally contributed to this work.
